Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.78 USD | +0.53% | +9.88% | +164.34% |
Apr. 30 | Chromadex Corp. Announces an Ingredient Partnership with Solgar | CI |
Apr. 23 | Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market | CI |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 64% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 945 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+164.34% | 285M | C- | ||
+25.69% | 47.86B | B- | ||
+46.90% | 41.42B | A | ||
-3.46% | 40.66B | B | ||
-6.20% | 28.92B | C | ||
+9.17% | 25.55B | B- | ||
-20.42% | 19.27B | B | ||
+0.17% | 12.15B | B+ | ||
+28.07% | 12.14B | C+ | ||
-1.24% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CDXC Stock
- Ratings ChromaDex Corporation